Novus therapeutics, inc. (NVUS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-16,011

-14,065

-13,116

-37,959

-45,087

-23,296

-15,725

-9,649

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

9

11

22

-

-

-

-

-

Amortization of operating lease asset

173

-

-

-

-

-

-

-

Goodwill impairment

1,867

0

-

-

-

-

-

-

Stock-based compensation

1,308

1,543

579

3,002

2,901

2,108

238

-

Loss on disposal of equipment

-

-

-49

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

210

Depreciation expense

-

-

-

171

109

21

10

9

Impairment of property and equipment

-

-

-

237

-

-

-

-

Release of reserve for loan to former advisor

-

-

-

-

49

158

-

-

Premium on purchase of marketable securities

-

-

-

2

186

-

-

-

Amortization of premium on marketable securities

-

-

-

-115

-72

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-354

476

517

-1,263

958

1,830

190

-139

Accounts payable and accrued expenses

-1,392

1,094

-1,958

-

-

-

-

-

Operating lease liability

-165

-

-

-

-

-

-

-

Net cash used in operating activities

-13,857

-11,893

-14,941

-

-

-

-

-

Accounts payable

-

-

-

-778

443

760

-759

-119

Accrued expenses

-

-

-

-2,565

1,476

1,274

950

77

Other assets

-

-

-

-

45

-

-

-

Other long-term liabilities

-

-

-

-4

88

-

-

-

Net cash used in operating activities

-

-

-

-36,520

-41,236

-21,121

-15,476

-9,333

Cash received from merger transaction

-

-

23,250

-

-

-

-

-

Proceeds from sale of equipment

-

-

8

-

-

-

-

-

Net cash provided by investing activities

-

-

23,258

-

-

-

-

-

Financing activities
Proceeds from maturities of marketable securities

-

-

-

36,200

-

-

-

-

Purchases of marketable securities

-

-

-

500

39,875

-

-

-

Purchase of property and equipment

-

-

-

17

565

25

23

8

Change in restricted cash

-

-

-

-

70

150

30

-

Net cash provided by (used in) investing activities

-

-

-

35,683

-40,510

-175

-53

-8

Proceeds from issuances of common stock, net

9,676

7,491

4,750

-

-

-

-

-

Proceeds from exercise of warrants, net

-

-

3,119

-

-

-

-

-

Proceeds from exercise of stock options

-

71

-

37

464

16

215

4

Net cash provided by financing activities

9,676

7,562

7,869

-

-

-

-

-

Repayment of notes receivable

-

-

-

-

49

158

-

-

Proceeds from initial public offering, net of underwriting discounts and commissions

-

-

-

-

-

97,929

-

-

Payments of initial public offering costs

-

-

-

-

-

3,304

30

-

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

35,406

18,775

Net cash provided by financing activities

-

-

-

37

513

94,799

35,591

18,779

Net change in cash

-4,181

-4,331

16,186

-

-

-

-

-

Conversion of promissory note and interest to common stock

-

-

3,447

-

-

-

-

-

Conversion of contingently issuable shares to common stock

-

-

291

-

-

-

-

-

Issuance of common stock in merger

-

-

23,375

-

-

-

-

-

Conversion of preferred shares to common stock

-

-

27

-

-

-

-

-

Fair value of assets acquired, excluding cash and restricted cash

-

-

3,072

-

-

-

-

-

Fair value of liabilities assumed

-

-

2,947

-

-

-

-

-

Fair value of net assets acquired in the merger

-

-

125

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-800

-81,233

73,503

20,062

9,438

Conversion of redeemable convertible preferred stock to common stock

-

-

-

-

-

-85,345

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

94

34

Conversion of convertible promissory notes and accrued interest and advance from stockholder to shares of redeemable convertible preferred stock

-

-

-

-

-

-

-

141